Fractyl
1 known investors
Fractyl develops therapies for obesity and type 2 diabetes, focusing on non-drug-based approaches rooted in understanding metabolic disease mechanisms. The company serves patients and the physician community seeking alternatives to lifelong pharmaceutical treatments.
BiotechHealthtechMedical Devices
Investors · 1
In the news
- Morgan Stanley reiterates Fractyl Health stock rating on weight maintenance data By Investing.cominvesting.com · 2026
- Fractyl Health reports one-year data from weight maintenance trial By Investing.cominvesting.com · 2026
- H.C. Wainwright reiterates Buy on Fractyl Health stock at $8 By Investing.cominvesting.com · 2026
- Fractyl Health (GUTS) Is Up 14.0% After First GLP-1 Gene Therapy Trial Win And Profit Turnaroundfinance.yahoo.com · 2026
- Fractyl Health Q1 2026 results and going concern risk | GUTS Quarterly Report (10-Q)stocktitan.net · 2026
- Fractyl Health Secures $20M Funding to Advance Revolutionary Diabetes and Obesity Therapeuticsstocktitan.net · 2025